Clinical trials: Perimenopausal Bone Loss
Postmenopause, Osteoporosis
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
The objectives of the study are to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) pain assessment at the beginning of the Preotact®…
- Trial name
- NCT00515593
- Testing
- Parathyroid hormone (PTH) (Preotact)
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Nycomed
Postmenopausal Osteoporosis
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
This is a single-center, randomized, open label, single-dose, the original drug controlled, crossover design, two sequence, two periods, Phase Ⅰclinical study.
- Trial name
- NCT04747392
- Testing
- SAL001, FORSTEO
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Postmenopausal Osteoporosis
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed…
- Trial name
- NCT00577421
- Testing
- risedronate
- Where
- 5 sites in Australia, Italy and 3 more
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.
- Trial name
- NCT02016716
- Testing
- Romosozumab 90 mg/mL, Romosozumab 70 mg/mL
- Where
- 12 sites in United States, Czechia and 1 more
- Volunteers
- 294 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- JULINA-CLIMA (NCT01386281)
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 506 people
- Sponsor
- Bayer
Osteoporosis
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.
- Trial name
- NCT00089791
- Testing
- Denosumab
- Volunteers
- 7,808 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.